B.S. (1973) – Purdue University, Indiana (Biochemistry)
Ph.D. (1977) – University of Kansas Medical Center (Biochemistry)
Postdoctoral Fellow (1978-81) – Duke University Medical Center, North Carolina (Biochemistry)
A Colorado resident, J. William (Bill) Freytag has over twenty-five years experience as an entrepreneur and executive leader in the biotechnology and pharmaceutical industries. Freytag currently serves as a member of the board of directors for three health care companies: GlobeImmune, Inc., BaroFold, Inc., and BiOptix Inc.
Doctor Freytag was Chairman and Chief Executive Officer of Aspreva Pharmaceuticals from July 2007 until its merger with Galenica AG in January 2008. Prior to Aspreva, Dr. Freytag was President, Chief Executive Officer and Chairman of the Board of Directors of Myogen, Inc. from July 1998 until Myogen was acquired by Gilead Sciences in November 2006.
From October 1994 to May 1998, Dr. Freytag was a Senior Vice President at Somatogen, Inc. Prior to Somatogen, he was President of Research and Development at Boehringer Mannheim Corporation, an international healthcare company, from May 1990 to September 1994. Previously, Dr. Freytag spent ten years with DuPont in various research and business positions in the Medical Products Department.
Doctor Freytag is also a member of the Board of Trustees of Colorado University Foundation; a member of the Board of the Deming Center for Entrepreneurship, Leeds School of Business, University of Colorado; a member of the Board of Trustees of Mount Desert Island Biological Laboratory; and a member of the Board of the Colorado University Institute for Molecular Biology.
In May 2011, Dr. Freytag was the recipient of the University of Colorado University Medal and an honorary degree in recognition of his instrumental role in the success of the Colorado Initiative in Molecular Biotechnology, which partners bioscience entrepreneurs with the University of Colorado.